MedPath

Effects of 3-months whole-body vibration training (WBV) in patients with interstitial lung disease: a randomized clinical trial.

Not Applicable
Conditions
J84
Other interstitial pulmonary diseases
Registration Number
DRKS00012930
Lead Sponsor
niversitätsklinikum Gießen und Marburg GmbHZentrum für Innere Medizin Schwerpunkt Pneumologie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
27
Inclusion Criteria

Inclusion criteria were: the diagnoses of ILD, idiopathic pulmonary fibrosis (IPF), Idiopathic nonspecific interstitial pneumonia (NSIP), acute interstitial pneumonia (AIP), Cryptogenic organizing pneumonia (COP) or Sarcoidosis, written informed consent.

Exclusion Criteria

- no pulmonary fibrosis
- sarcoidosis
- withdrawn consent
- Indication of acute pathological cardiac events in the laboratory or ECG (TNI or CK increase, new ST segment changes).
- Concomitant diseases such as heart failure (NYHA III and IV) or COPD
- decompensated cardiac insufficiency
- high blood pressure (>220/120 mmHg)
- more serious mental illnesses
- cognitive limitations
- Restrictions of the musculoskeletal system that make training with the Galileo impossible:
? Acute thrombosis
? Implants in trained body regions
? Acute Arthrosis
? Acute tendinopathy
? Acute hernia
? Acute discopathy
? Fresh Fractures
? Fresh wounds and/or scars
- neurological diseases that affect training and performance
- acute exacerbations in the last 3 months
- acute inflammation/infections up to 4 weeks before inclusion
- Change in antifibrotic therapy in the last 3 months or participation in a lung sport

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measuring the performance of the patients based on the % of modification of 6 minutes walking distance after 3 months in comparison to the baseline study and the Sham-training control group.<br>The investigations took place at the time of enrollment (t0) and after 3 months (t1).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath